Mevrometostat

N/A

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameMevrometostat
Drug Alias NamePF-06821497PF-6821497
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone-lysine N-methyltransferase EZH2 inhibitors
TargetsHistone-lysine N-methyltransferase EZH2
Therapy Area/IndicationsCastration-Sensitive Prostate NeoplasmsHormone-Sensitive Prostate NeoplasmsProstatic Neoplasms, Castration-Resistant +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[33] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer LtdPfizer IncNa Pharma Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsCastration-Sensitive Prostate NeoplasmsHormone-Sensitive Prostate NeoplasmsProstatic Neoplasms, Castration-Resistant +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksKEGG